Administration of testosterone produced a pain phenotype which was unilateral and short-lasting regardless of sex. Of note, four-weeks of transdermal testosterone administration to women with fibromyalgia improved muscle pain, stiffness, and fatigue . While female hyperalgesia is produced by an alternative pathway activating the adaptive immune system . The current study modulated testosterone in adult mice and therefore examined if activational effects were responsible for induction of a phenotypic sex difference. Thus, testosterone during development alters the central nervous system to protect male mice from development of hyperalgesia. While some studies show a sex-dependent phenotype, others show no difference in the phenotype in a variety of animal models of pain including neuropathic and inflammatory 48;57. The current study is the first to show testosterone impacts development of widespread muscle pain suggesting that testosterone could protect against development of widespread pain and potentially modulate SERT expression in the NRM.
It provides structural support to your body and protects your muscles. They focus on releasing tension in your fascial tissues. As research progresses, MFR therapy may become an increasingly integral component of comprehensive pelvic health care. However, to ensure safety and maximize benefits, it is essential to seek treatment from qualified pelvic health professionals. Over eight weeks, the patient reported a significant reduction in pain, improved erectile function, and enhanced urinary control. Regular follow-ups and reassessments ensure that the therapy remains aligned with the patient's evolving needs.
These sexual differences found for severity, duration, and alleviation of pain suggest the presence of a sexually dimorphic mechanism underlying chronic pain. Females show a greater incidence of chronic pain conditions including headache, osteoarthritis, rheumatoid arthritis, irritable bowel syndrome, and fibromyalgia 22;45;63. Prior studies show that the serotonin transporter (SERT) is increased in the nucleus raphe magnus (NRM) in models of chronic pain, and that blockade of SERT in the NRM reduces hyperalgesia. It may also be referred to as 'myofascial trigger point therapy' by others. For this reason, myofascial therapy is sometimes referred to as 'myofascial release' therapy. Other conditions treated by myofascial release therapy include Temporo-Mandibular Joint (TMJ) disorder, carpal tunnel syndrome, or possibly fibromyalgia or migraine headaches. There are a number of conditions and symptoms that myofascial release therapy addresses.
This pattern causes it to be widely misinterpreted as back pain and/or sciatica, when in fact it’s just a sore spot in the butt. Many people have a sore spot in the upper gluteus maximus, but pain in this location often spreads either up into the low back and/or down into the rest of the gluteals and hamstrings. This is where trigger points really get interesting. But in many cases it’s probably just a trigger point — about as serious as banging your funny bone. Got a bizarre pain that just flared up one day?
Lastly, sex steroids have immunomodulatory properties with testosterone increasing release of anti-inflammatory cytokines (interleukin-10) and decreasing release of pro-inflammatory cytokines (interleukin-1β, interleukin-6) from macrophages and lymphocytes 2;38;69. Several studies show the immune system is differentially activated in male and female mice. Classically sex-dependent effects are thought to be a result of either organizational or activational effects. The reason for these differences is unclear and could be related to the animal model, the behavioral test used, or different underlying mechanisms producing the same phenotype.
The brains and lumbar spinal cords were removed and stored in 30% sucrose in PBS overnight (4°C), tissues were then frozen in cryomolds (OCT, Tissue Tek, Fisher Scientific, Waltham, MA) at −20°C. We have previously shown increases in SERT in the rostral ventral medial medulla (RVM) following induction of neuropathic pain . Immunohistochemistry was done in animals that received two injections of pH 5.0 with muscle stimulation and compared to a control group that received two injections of pH 7.2 with muscle stimulation.
Orchiectomy (Orx) of males 2 weeks prior to induction of pain model resulted in MWT changes similar to females. For immunohistochemistry data, a two-way ANOVA tested differences by the pain model (pH 5.0 vs. pH 7.2), sex (male vs. female) and an interaction between the pain model and sex. This experiment tested if orchiectomy could reverse the sex-dependent effects observed in pain behavior between males and females. This protocol was found to produce sex-dependent effects in which males do not develop decreases in muscle withdrawal thresholds while females have significant decreases in muscle withdrawal thresholds bilaterally . This protocol produces sex-dependent effects in which males do not develop decreases in muscle withdrawal thresholds while females have significant decreases in muscle withdrawal thresholds bilaterally . This protocol produces sex-dependent effects in which males have unilateral, shorter lasting decrease in muscle withdrawal threshold compared to females .
Removal of testosterone by orchiectomy in males produced bilateral, longer-lasting hyperalgesia similar to females. The current study shows testosterone mediates the sex-dependent phenotype observed in an activity-induced pain model. To determine if there were sex differences in SERT staining following induction of the activity-induced pain model, we compared SERT immunoreactivity in various brain regions. Taken together this data demonstrate hyperalgesia is more easily induced in orchiectomized mice similar to females. (A) Changes in muscle withdrawal threshold following the activity-induced pain model resulted in hyperalgesia ipsilaterally. (A-D) Changes in muscle withdrawal threshold from baseline values over a 4-week time period for the ipsilateral and contralateral muscle in females (A&B) or orchiectomized males (C&D) receiving either testosterone or placebo administration. Group differences in MWT following 2-week administration of testosterone prior to induction of activity induced pain model.

Gender: Female

Social links